Chemours (NYSE:CC) Trading Up 6.4% - Time to Buy?

The Chemours Company (NYSE:CC - Get Free Report)'s stock price traded up 6.4% during trading on Thursday . The stock traded as high as $14.48 and last traded at $14.65. 732,148 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 3,420,500 shares. The stock had previously closed at $13.77.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Royal Bank Of Canada increased their target price on Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. Wall Street Zen lowered Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. The Goldman Sachs Group dropped their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, May 14th. Truist Financial dropped their target price on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Morgan Stanley dropped their target price on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $17.33.

Chemours Stock Down 1.7%

The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 69.05 and a beta of 1.65. The firm's 50 day simple moving average is $11.38 and its 200-day simple moving average is $13.91.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 23.82% and a net margin of 0.54%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the company posted $0.32 EPS. Chemours's quarterly revenue was up .4% on a year-over-year basis. As a group, sell-side analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently announced a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were paid a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio (DPR) is 175.00%.

Insider Activity

In other Chemours news, CFO Shane Hostetter bought 4,450 shares of the firm's stock in a transaction dated Monday, May 19th. The stock was acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the purchase, the chief financial officer owned 59,694 shares of the company's stock, valued at approximately $673,348.32. This represents a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Damian Gumpel purchased 7,822 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average cost of $9.95 per share, with a total value of $77,828.90. Following the completion of the acquisition, the insider directly owned 131,701 shares of the company's stock, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 25,672 shares of company stock valued at $251,573 in the last quarter. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CC. FNY Investment Advisers LLC purchased a new position in Chemours during the first quarter worth about $27,000. UMB Bank n.a. raised its holdings in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares in the last quarter. SouthState Corp purchased a new position in Chemours during the first quarter worth about $34,000. Finally, Quadrant Capital Group LLC raised its holdings in Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.